Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 57 results for tuberculosis

  1. For people with active, drug susceptible TB who experience treatment interruptions because of adverse events, particularly hepatotoxicity, what approach to re-establishing treatment is mosteffective in reducing mortality and morbidity?

    ID NG33/5 Question For people with active, drug susceptible TB who experience treatment interruptions because of adverse events,...

    Research recommendation
    Published
    8 November 2019

  2. Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis

    Discontinued [GID-DT9]

    Diagnostics guidance
    Discontinued

  3. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they have not worked well enough.

    Technology appraisal guidance
    Published
    25 August 2010
    View recommendations

    Sections for TA195

  4. Committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  5. Artificial intelligence for analysing chest CT images (MIB243)

    NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing chest CT images .

    Medtech innovation briefing
    Published
    5 January 2021

  6. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)

    Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.

    Technology appraisal guidance
    Published
    25 February 2015
    View recommendations

    Sections for TA329

  7. Antimicrobial stewardship: changing risk-related behaviours in the general population (NG63)

    This guideline covers making people aware of how to correctly use antimicrobial medicines (including antibiotics) and the dangers associated with their overuse and misuse. It also includes measures to prevent and control infection that can stop people needing antimicrobials or spreading infection to others. It aims to change people’s behaviour to reduce antimicrobial resistance and the spread of resistant microbes.

    NICE guideline
    Published
    25 January 2017
    View recommendations

    Sections for NG63

  8. Our projects and partners

    NICE research projects and partners.

  9. High-risk groups:- What interventions to prevent infection and reduce antimicrobial resistance are effective for groups of people at high risk of infection? This includes people who:- have suppressed immune systems (for example, because of HIV, an inherited condition or treatment they may be having for conditions such as cancer or an organ transplant)- have a chronic disease- live in crowded conditions (see Shelter's definition)- are homeless- have been in prison- have migrated from countries with a high prevalence of infectious diseases such as tuberculosis (examples include South Asia and sub-Saharan Africa).

    from countries with a high prevalence of infectious diseases such as tuberculosis (examples include South Asia and sub-Saharan Africa)....

    Research recommendation
    Published
    17 February 2017

  10. Infliximab for the treatment of adults with psoriasis (TA134)

    Evidence-based recommendations on infliximab for treating severe psoriasis in adults.

    Technology appraisal guidance
    Published
    23 January 2008
    View recommendations

    Sections for TA134

  11. Adalimumab for the treatment of adults with psoriasis (TA146)

    Evidence-based recommendations on adalimumab (Humira) for treating psoriasis in adults.

    Technology appraisal guidance
    Published
    25 June 2008
    View recommendations

    Sections for TA146

  12. Golimumab for the treatment of psoriatic arthritis (TA220)

    Evidence-based recommendations on golimumab (Simponi) for treating psoriatic arthritis in adults.

    Technology appraisal guidance
    Published
    27 April 2011
    View recommendations

    Sections for TA220

  13. Infliximab for acute exacerbations of ulcerative colitis (TA163)

    Evidence-based recommendations on infliximab (Remicade) for treating acute exacerbations of severely active ulcerative colitis in adults.

    Technology appraisal guidance
    Published
    17 December 2008
    View recommendations

    Sections for TA163

  14. Methods research areas

    NICE priority methodological research areas.

  15. Vaccine uptake in under 19s (QS145)

    This quality standard covers increasing vaccine uptake among children and young people aged under 19 in groups and settings that have low immunisation coverage. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    17 May 2022
    View quality statements

    Sections for QS145